nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentazocine—Hepatic function abnormal—Sorafenib—liver cancer	0.0346	0.0346	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.0272	0.0272	CcSEcCtD
Pentazocine—Abdominal discomfort—Sorafenib—liver cancer	0.025	0.025	CcSEcCtD
Pentazocine—Nystagmus—Epirubicin—liver cancer	0.0215	0.0215	CcSEcCtD
Pentazocine—Nystagmus—Doxorubicin—liver cancer	0.0199	0.0199	CcSEcCtD
Pentazocine—Erythema multiforme—Sorafenib—liver cancer	0.0198	0.0198	CcSEcCtD
Pentazocine—Tinnitus—Sorafenib—liver cancer	0.0195	0.0195	CcSEcCtD
Pentazocine—Flushing—Sorafenib—liver cancer	0.0194	0.0194	CcSEcCtD
Pentazocine—Dysgeusia—Sorafenib—liver cancer	0.0178	0.0178	CcSEcCtD
Pentazocine—Muscle spasms—Sorafenib—liver cancer	0.0175	0.0175	CcSEcCtD
Pentazocine—Syncope—Sorafenib—liver cancer	0.0163	0.0163	CcSEcCtD
Pentazocine—Ulcer—Epirubicin—liver cancer	0.0163	0.0163	CcSEcCtD
Pentazocine—Loss of consciousness—Sorafenib—liver cancer	0.016	0.016	CcSEcCtD
Pentazocine—Hypertension—Sorafenib—liver cancer	0.0157	0.0157	CcSEcCtD
Pentazocine—Dry mouth—Sorafenib—liver cancer	0.0152	0.0152	CcSEcCtD
Pentazocine—Ulcer—Doxorubicin—liver cancer	0.0151	0.0151	CcSEcCtD
Pentazocine—Anaphylactic shock—Sorafenib—liver cancer	0.0149	0.0149	CcSEcCtD
Pentazocine—Shock—Sorafenib—liver cancer	0.0146	0.0146	CcSEcCtD
Pentazocine—Anorexia—Sorafenib—liver cancer	0.0142	0.0142	CcSEcCtD
Pentazocine—Dyspnoea—Sorafenib—liver cancer	0.0132	0.0132	CcSEcCtD
Pentazocine—Decreased appetite—Sorafenib—liver cancer	0.0129	0.0129	CcSEcCtD
Pentazocine—Hepatic function abnormal—Epirubicin—liver cancer	0.0128	0.0128	CcSEcCtD
Pentazocine—Constipation—Sorafenib—liver cancer	0.0127	0.0127	CcSEcCtD
Pentazocine—Hepatic function abnormal—Doxorubicin—liver cancer	0.0118	0.0118	CcSEcCtD
Pentazocine—Diplopia—Epirubicin—liver cancer	0.0112	0.0112	CcSEcCtD
Pentazocine—Hypersensitivity—Sorafenib—liver cancer	0.0109	0.0109	CcSEcCtD
Pentazocine—Face oedema—Epirubicin—liver cancer	0.0108	0.0108	CcSEcCtD
Pentazocine—Asthenia—Sorafenib—liver cancer	0.0107	0.0107	CcSEcCtD
Pentazocine—Pruritus—Sorafenib—liver cancer	0.0105	0.0105	CcSEcCtD
Pentazocine—Diplopia—Doxorubicin—liver cancer	0.0103	0.0103	CcSEcCtD
Pentazocine—Diarrhoea—Sorafenib—liver cancer	0.0102	0.0102	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.0101	0.0101	CcSEcCtD
Pentazocine—Face oedema—Doxorubicin—liver cancer	0.00998	0.00998	CcSEcCtD
Pentazocine—Dizziness—Sorafenib—liver cancer	0.00982	0.00982	CcSEcCtD
Pentazocine—Eosinophilia—Epirubicin—liver cancer	0.00956	0.00956	CcSEcCtD
Pentazocine—Vomiting—Sorafenib—liver cancer	0.00945	0.00945	CcSEcCtD
Pentazocine—Dermatitis—Sorafenib—liver cancer	0.00936	0.00936	CcSEcCtD
Pentazocine—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.00931	0.00931	CcSEcCtD
Pentazocine—Headache—Sorafenib—liver cancer	0.00931	0.00931	CcSEcCtD
Pentazocine—Eosinophilia—Doxorubicin—liver cancer	0.00885	0.00885	CcSEcCtD
Pentazocine—Nausea—Sorafenib—liver cancer	0.00882	0.00882	CcSEcCtD
Pentazocine—Sweating—Epirubicin—liver cancer	0.00825	0.00825	CcSEcCtD
Pentazocine—Agranulocytosis—Epirubicin—liver cancer	0.00803	0.00803	CcSEcCtD
Pentazocine—Sweating—Doxorubicin—liver cancer	0.00764	0.00764	CcSEcCtD
Pentazocine—Visual impairment—Epirubicin—liver cancer	0.00745	0.00745	CcSEcCtD
Pentazocine—Agranulocytosis—Doxorubicin—liver cancer	0.00743	0.00743	CcSEcCtD
Pentazocine—Erythema multiforme—Epirubicin—liver cancer	0.00731	0.00731	CcSEcCtD
Pentazocine—Tinnitus—Epirubicin—liver cancer	0.00721	0.00721	CcSEcCtD
Pentazocine—Flushing—Epirubicin—liver cancer	0.00717	0.00717	CcSEcCtD
Pentazocine—Chills—Epirubicin—liver cancer	0.00693	0.00693	CcSEcCtD
Pentazocine—Visual impairment—Doxorubicin—liver cancer	0.00689	0.00689	CcSEcCtD
Pentazocine—Erythema multiforme—Doxorubicin—liver cancer	0.00676	0.00676	CcSEcCtD
Pentazocine—Tinnitus—Doxorubicin—liver cancer	0.00667	0.00667	CcSEcCtD
Pentazocine—Flushing—Doxorubicin—liver cancer	0.00664	0.00664	CcSEcCtD
Pentazocine—Dysgeusia—Epirubicin—liver cancer	0.00659	0.00659	CcSEcCtD
Pentazocine—Muscle spasms—Epirubicin—liver cancer	0.00647	0.00647	CcSEcCtD
Pentazocine—Chills—Doxorubicin—liver cancer	0.00642	0.00642	CcSEcCtD
Pentazocine—Vision blurred—Epirubicin—liver cancer	0.00634	0.00634	CcSEcCtD
Pentazocine—Agitation—Epirubicin—liver cancer	0.00618	0.00618	CcSEcCtD
Pentazocine—Dysgeusia—Doxorubicin—liver cancer	0.0061	0.0061	CcSEcCtD
Pentazocine—Vertigo—Epirubicin—liver cancer	0.00604	0.00604	CcSEcCtD
Pentazocine—Syncope—Epirubicin—liver cancer	0.00603	0.00603	CcSEcCtD
Pentazocine—Muscle spasms—Doxorubicin—liver cancer	0.00598	0.00598	CcSEcCtD
Pentazocine—Loss of consciousness—Epirubicin—liver cancer	0.00591	0.00591	CcSEcCtD
Pentazocine—Vision blurred—Doxorubicin—liver cancer	0.00587	0.00587	CcSEcCtD
Pentazocine—Hypertension—Epirubicin—liver cancer	0.00581	0.00581	CcSEcCtD
Pentazocine—Agitation—Doxorubicin—liver cancer	0.00572	0.00572	CcSEcCtD
Pentazocine—Dry mouth—Epirubicin—liver cancer	0.0056	0.0056	CcSEcCtD
Pentazocine—Vertigo—Doxorubicin—liver cancer	0.00559	0.00559	CcSEcCtD
Pentazocine—Syncope—Doxorubicin—liver cancer	0.00558	0.00558	CcSEcCtD
Pentazocine—Confusional state—Epirubicin—liver cancer	0.00554	0.00554	CcSEcCtD
Pentazocine—Anaphylactic shock—Epirubicin—liver cancer	0.00549	0.00549	CcSEcCtD
Pentazocine—Loss of consciousness—Doxorubicin—liver cancer	0.00547	0.00547	CcSEcCtD
Pentazocine—Shock—Epirubicin—liver cancer	0.0054	0.0054	CcSEcCtD
Pentazocine—Hypertension—Doxorubicin—liver cancer	0.00537	0.00537	CcSEcCtD
Pentazocine—Tachycardia—Epirubicin—liver cancer	0.00536	0.00536	CcSEcCtD
Pentazocine—Hyperhidrosis—Epirubicin—liver cancer	0.00531	0.00531	CcSEcCtD
Pentazocine—Anorexia—Epirubicin—liver cancer	0.00523	0.00523	CcSEcCtD
Pentazocine—Dry mouth—Doxorubicin—liver cancer	0.00518	0.00518	CcSEcCtD
Pentazocine—Hypotension—Epirubicin—liver cancer	0.00513	0.00513	CcSEcCtD
Pentazocine—Confusional state—Doxorubicin—liver cancer	0.00512	0.00512	CcSEcCtD
Pentazocine—Anaphylactic shock—Doxorubicin—liver cancer	0.00508	0.00508	CcSEcCtD
Pentazocine—Shock—Doxorubicin—liver cancer	0.005	0.005	CcSEcCtD
Pentazocine—Insomnia—Epirubicin—liver cancer	0.00497	0.00497	CcSEcCtD
Pentazocine—Tachycardia—Doxorubicin—liver cancer	0.00496	0.00496	CcSEcCtD
Pentazocine—Paraesthesia—Epirubicin—liver cancer	0.00493	0.00493	CcSEcCtD
Pentazocine—Hyperhidrosis—Doxorubicin—liver cancer	0.00491	0.00491	CcSEcCtD
Pentazocine—Dyspnoea—Epirubicin—liver cancer	0.00489	0.00489	CcSEcCtD
Pentazocine—Somnolence—Epirubicin—liver cancer	0.00488	0.00488	CcSEcCtD
Pentazocine—Anorexia—Doxorubicin—liver cancer	0.00484	0.00484	CcSEcCtD
Pentazocine—Decreased appetite—Epirubicin—liver cancer	0.00477	0.00477	CcSEcCtD
Pentazocine—Hypotension—Doxorubicin—liver cancer	0.00475	0.00475	CcSEcCtD
Pentazocine—Constipation—Epirubicin—liver cancer	0.0047	0.0047	CcSEcCtD
Pentazocine—Insomnia—Doxorubicin—liver cancer	0.00459	0.00459	CcSEcCtD
Pentazocine—Paraesthesia—Doxorubicin—liver cancer	0.00456	0.00456	CcSEcCtD
Pentazocine—Dyspnoea—Doxorubicin—liver cancer	0.00453	0.00453	CcSEcCtD
Pentazocine—Feeling abnormal—Epirubicin—liver cancer	0.00452	0.00452	CcSEcCtD
Pentazocine—Somnolence—Doxorubicin—liver cancer	0.00452	0.00452	CcSEcCtD
Pentazocine—Decreased appetite—Doxorubicin—liver cancer	0.00442	0.00442	CcSEcCtD
Pentazocine—Constipation—Doxorubicin—liver cancer	0.00434	0.00434	CcSEcCtD
Pentazocine—Feeling abnormal—Doxorubicin—liver cancer	0.00419	0.00419	CcSEcCtD
Pentazocine—Hypersensitivity—Epirubicin—liver cancer	0.00405	0.00405	CcSEcCtD
Pentazocine—Asthenia—Epirubicin—liver cancer	0.00394	0.00394	CcSEcCtD
Pentazocine—Pruritus—Epirubicin—liver cancer	0.00388	0.00388	CcSEcCtD
Pentazocine—Diarrhoea—Epirubicin—liver cancer	0.00376	0.00376	CcSEcCtD
Pentazocine—Hypersensitivity—Doxorubicin—liver cancer	0.00374	0.00374	CcSEcCtD
Pentazocine—Asthenia—Doxorubicin—liver cancer	0.00364	0.00364	CcSEcCtD
Pentazocine—Dizziness—Epirubicin—liver cancer	0.00363	0.00363	CcSEcCtD
Pentazocine—Pruritus—Doxorubicin—liver cancer	0.00359	0.00359	CcSEcCtD
Pentazocine—Vomiting—Epirubicin—liver cancer	0.00349	0.00349	CcSEcCtD
Pentazocine—Diarrhoea—Doxorubicin—liver cancer	0.00348	0.00348	CcSEcCtD
Pentazocine—Dermatitis—Epirubicin—liver cancer	0.00346	0.00346	CcSEcCtD
Pentazocine—Headache—Epirubicin—liver cancer	0.00344	0.00344	CcSEcCtD
Pentazocine—Dizziness—Doxorubicin—liver cancer	0.00336	0.00336	CcSEcCtD
Pentazocine—Nausea—Epirubicin—liver cancer	0.00326	0.00326	CcSEcCtD
Pentazocine—Vomiting—Doxorubicin—liver cancer	0.00323	0.00323	CcSEcCtD
Pentazocine—Dermatitis—Doxorubicin—liver cancer	0.0032	0.0032	CcSEcCtD
Pentazocine—Headache—Doxorubicin—liver cancer	0.00318	0.00318	CcSEcCtD
Pentazocine—Nausea—Doxorubicin—liver cancer	0.00302	0.00302	CcSEcCtD
